AbCellera Biologics (ABCL) Leases: 2021-2025
Historic Leases for AbCellera Biologics (ABCL) over the last 4 years, with Sep 2025 value amounting to $137.9 million.
- AbCellera Biologics' Leases rose 101.87% to $137.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.9 million, marking a year-over-year increase of 101.87%. This contributed to the annual value of $66.6 million for FY2024, which is 8.88% down from last year.
- As of Q3 2025, AbCellera Biologics' Leases stood at $137.9 million, which was up 0.71% from $136.9 million recorded in Q2 2025.
- In the past 5 years, AbCellera Biologics' Leases registered a high of $137.9 million during Q3 2025, and its lowest value of $6.6 million during Q1 2022.
- Over the past 3 years, AbCellera Biologics' median Leases value was $72.5 million (recorded in 2023), while the average stood at $83.7 million.
- As far as peak fluctuations go, AbCellera Biologics' Leases spiked by 632.47% in 2023, and later dropped by 26.17% in 2025.
- Over the past 5 years, AbCellera Biologics' Leases (Quarterly) stood at $19.8 million in 2021, then skyrocketed by 308.27% to $80.8 million in 2022, then dropped by 9.52% to $73.1 million in 2023, then fell by 8.88% to $66.6 million in 2024, then spiked by 101.87% to $137.9 million in 2025.
- Its Leases was $137.9 million in Q3 2025, compared to $136.9 million in Q2 2025 and $68.7 million in Q1 2025.